A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 6, 2008, Pages 944-950

  Shlansky Goldberg, R D ^a   Matsumoto, A H ^b   Baumbach, G A ^c   Siegel, J B ^d   Raabe, R D ^e   Murphy, T P ^f   Deng, C ^c   Ray Dawkins, J ^c   Marder, V J ^g  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c Talecris Biotherapeutics Inc   (United States)

^d Dallas Nephrology Associates   (United States)

^e SACRED HEART MEDICAL CENTER   (United States)

^f RHODE ISLAND HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Catheters; Kidney; Shunts; Thrombolysis

Indexed keywords

ALPHA 2 ANTIPLASMIN; BAY 57 9602; FIBRINOGEN; HEPARIN; PLASMIN; TAL 05 00018;

ADULT; AGED; ANGINA PECTORIS; ANGIOGRAPHY; ANGIONEUROTIC EDEMA; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIALYSIS CATHETER; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYTIC THERAPY; FISTULOGRAPHY; GRAFT OCCLUSION; HEMODIALYSIS; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; PLASMIN; RENAL DIALYSIS; THROMBOLYTIC THERAPY; THROMBOSIS;

EID: 43749084383     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02969.x     Document Type: Article

References (27)

1. Marder VJ, Stewart D. Towards safer thrombolytic therapy. Semin Hematol 2002; 39: 206-16.
2. Wiman B, Lijnen HR, Collen D. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta 1979; 579: 142-54.
3. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
4. Marder VJ. The use of thrombolytic agents: Choice of patient, drug administration, laboratory monitoring. Ann Intern Med 1979; 90: 802-8.
5. Dotter CT, Rosch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974; 111: 31-7.
6. Ouriel K, Gray B, Clair DG, Olin J. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol 2000; 11: 295-8.
7. Henkin J, Marcotte P, Yang HC. The plasminogen-plasmin system. Prog Cardiovasc Dis 1991; 34: 135-64.
8. Novokhatny VV, Jesmok GJ, Landskroner KA, Marder VJ, Zimmerman TP. Locally delivered plasmin: Why should it be superior to plasminogen activators for direct thrombolysis? Trends Pharmacol Sci 2004; 25: 72-5.
9. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, Jesmok G. Plasmin induces local thrombolysis without causing hemorrhage: A comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86: 739-45.
10. Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood 2003; 101: 3002-7.
11. Bookstein JJ, Fellmeth B, Roberts A, Valji K, Davis G, Machado T. Pulsed-spray pharmacomechanical thrombolysis: Preliminary clinical results. AJR Am J Roentgenol 1989; 152: 1097-100.
12. Valji K. Transcatheter treatment of thrombosed hemodialysis access grafts. AJR Am J Roentgenol 1995; 164: 823-9.
13. Sofocleous CT, Hinrichs CR, Weiss SH, Contractor D, Barone A, Bahramipour P, Brountzos E, Kelekis D. Alteplase for hemodialysis access graft thrombolysis. J Vasc Interv Radiol 2002; 13: 775-83.
14. Middlebrook MR, Amygdalos MA, Soulen MC, Haskal ZJ, Shlansky-Goldberg RD, Cope C, Pentecost MJ. Thrombosed hemodialysis grafts: Percutaneous mechanical balloon declotting versus thrombolysis. Radiology 1995; 196: 73-7.
15. Novokhatny V, Taylor K, Zimmerman TP. Thrombolytic potency of acid-stabilized plasmin: Superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost 2003; 1: 1034-41.
16. Chase T Jr, Shaw E. Comparison of the esterase activities of trypsin, plasmin, and thrombin on guanidinobenzoate esters: Titration of the enzymes. Biochemistry 1969; 8: 2212-24.
17. The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction TIMI IIA results. JAMA 1988; 260: 2849-58.
18. Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-45.
19. Ellis BC, Stransky A. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 1961; 58: 477-88.
20. Valji K, Bookstein JJ, Roberts AC, Oglevie SB, Pittman C, O'Neill MP. Pulse-spray pharmacomechanical thrombolysis of thrombosed hemodialysis access grafts: Long-term experience and comparison of original and current techniques. AJR Am J Roentgenol 1995; 164: 1495-500.
21. Falk A, Guller J, Nowakowski FS, Mitty H, Teodorescu V, Uribarri J, Vassalotti J. Reteplase in the treatment of thrombosed hemodialysis grafts. J Vasc Interv Radiol 2001; 12: 1257-62.
22. Falk A, Harbour K. Tenecteplase in the treatment of thrombosed hemodialysis grafts. Cardiovasc Intervent Radiol 2005; 28: 472-5.
23. Cliffton EE. Review of clinical experience with clot-lysing agents. Am J Cardiol 1960; 6: 476-86.
24. Moser KM. Thrombolysis with fibrinolysin (plasmin): New therapeutic approach to thromboembolism. J Am Med Assoc 1958; 167: 1695-704.
25. Alkjaersig N, Fletcher AP, Sherry S. The mechanism of clot dissolution by plasmin. J Clin Invest 1959; 38: 1086-95.
26. Marder VJ, Chute DJ, Starkman S, Abolian AM, Kidwell C, Liebeskind D, Ovbiagele B, Vinuela F, Duckwiler G, Jahan R, Vespa PM, Selco S, Rajajee V, Kim D, Sanossian N, Saver JL. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke 2006; 37: 2086-93.
27. Comerota AJ, Marder VJ, Dawkins R. The PRIORITY trial: Plasmin revascularization of acute lower extremity native artery or bypass graft occlusion-phase I/II protocol design. J Thromb Haemost 2007; 5 (Suppl. 2): P-S-691.